Day: October 9, 2025

NEW YORK, NY, Oct. 09, 2025 (GLOBE NEWSWIRE) — Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announces the addition of Dr. Laura A. Philips to its board of directors as an independent director at closing of the merger with DiamiR Biosciences Corp.  Dr. Philips is the co-founder, President, and Chief Executive Officer of Spheryx, Inc., a technology company developing holographic microscopic techniques for a broad range of applications in areas including the pharmaceutical industry, semiconductor manufacturing, cosmetics, consumer products, quality assurance, and process control. In addition to co-founding Spheryx in 2014, Dr. Philips has served on the Boards of Directors of multiple private and public life sciences...

 With over 120 issued and pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation Newly issued patent strengthens the Company’s strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases THE WOODLANDS, TX, Oct. 09, 2025 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,369,852 (the ‘852 patent), titled, “Controlled and Precise Treatment of Cardiac Tissues.” The newly issued ‘852 patent covers systems, devices, and methods that sense autonomic/cardiac signals,...

BOSTON and LONDON, Oct. 09, 2025 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed two new provisional patent applications with the United States Patent and Trademark Office (USPTO). The first application includes claims protecting Akari’s novel immuno-oncology payload, PH1 (a novel Thailanstatin analog), and its spliceosome modulatory mechanism of action, which is expected to provide a therapeutic benefit by activating the host immune system in the fight against cancer. The second patent filing includes claims for a combination therapy of PH1 pipeline ADCs with other immuno-oncology drugs that alleviate checkpoint inhibition and have demonstrated synergy with immune checkpoint inhibitors (ICIs)...

Petah Tikvah, Israel, Oct. 09, 2025 (GLOBE NEWSWIRE) — SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology company specializing in developing transportation safety solutions, today announced that TIME revealed its annual list of the Best Inventions, which features 300 extraordinary innovations that are changing lives. Included in this year’s list is the SaverOne System, which proactively detects and blocks unsafe phone use in real time, preventing distractions before they become a risk to drivers. This prestigious recognition from TIME highlights SaverOne’s commitment to leveraging cutting-edge technology to address a critical safety issue. With distracted driving continuing to rank among the top causes of accidents worldwide, the acknowledgment places SaverOne alongside some of the world’s most impactful and forward-looking...

TORONTO, Oct. 09, 2025 (GLOBE NEWSWIRE) — DPM Metals Inc. (TSX: DPM, ASX: DPM) (ARBN: 689370894) (“DPM” or “the Company”) announced preliminary production results for the three and nine months ended September 30, 2025. “The integration of Vareš into our operating portfolio is proceeding well. As we advance our priorities to achieve full production at Vareš by the end of 2026, we continue to be excited about the growth potential of this high-quality asset,” said David Rae, President and Chief Executive Officer. “We continue to deliver solid, consistent results from our operations, with gold and copper production increasing in the third quarter as planned. Both mines are on track to achieve our 2025 guidance.” Production Highlights Preliminary results for the three and nine months ended September 30, 2025, for the Chelopech and Ada...